158 related articles for article (PubMed ID: 14602752)
41. Effect of raloxifene hydrochloride on bone mineral density and bone turnover in Kuwaiti postmenopausal women with osteoporosis.
Abdelazim IA; Abdelrazak KM; Al-Kadi M; Yehia AH; Nusair BM; Faza MA
Arch Osteoporos; 2014; 9():189. PubMed ID: 25037077
[TBL] [Abstract][Full Text] [Related]
42. Consistency of bone turnover marker and calcium responses to parathyroid hormone (1-84) therapy in postmenopausal osteoporosis.
Schafer AL; Palermo L; Bauer DC; Bilezikian JP; Sellmeyer DE; Black DM
J Clin Densitom; 2011; 14(1):68-73. PubMed ID: 21095149
[TBL] [Abstract][Full Text] [Related]
43. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal.
Cosman F; Nieves J; Woelfert L; Formica C; Gordon S; Shen V; Lindsay R
J Bone Miner Res; 2001 May; 16(5):925-31. PubMed ID: 11341338
[TBL] [Abstract][Full Text] [Related]
44. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.
Bone HG; Bolognese MA; Yuen CK; Kendler DL; Miller PD; Yang YC; Grazette L; San Martin J; Gallagher JC
J Clin Endocrinol Metab; 2011 Apr; 96(4):972-80. PubMed ID: 21289258
[TBL] [Abstract][Full Text] [Related]
45. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
Murphy MG; Weiss S; McClung M; Schnitzer T; Cerchio K; Connor J; Krupa D; Gertz BJ;
J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495
[TBL] [Abstract][Full Text] [Related]
46. Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis: a multi-center, randomized, placebo-controlled clinical trial.
Liu JL; Zhu HM; Huang QR; Zhang ZL; Li HL; Qin YJ; Zhang Y; Wei DL; Lu JH; Liu H; Chen XP; Liu YJ; Ekangaki A; Zheng YM; Diez-Perez A; Harper K
Chin Med J (Engl); 2004 Jul; 117(7):1029-35. PubMed ID: 15265377
[TBL] [Abstract][Full Text] [Related]
47. Double-blind, placebo-controlled study of the effects of tibolone on bone mineral density in postmenopausal osteoporotic women with and without previous fractures.
Pavlov PW; Ginsburg J; Kicovic PM; van der Schaaf DB; Prelevic G; Bennink HJ
Gynecol Endocrinol; 1999 Aug; 13(4):230-7. PubMed ID: 10533157
[TBL] [Abstract][Full Text] [Related]
48. Six months of parathyroid Hormone (1-84) administered concurrently versus sequentially with monthly ibandronate over two years: the PTH and ibandronate combination study (PICS) randomized trial.
Schafer AL; Sellmeyer DE; Palermo L; Hietpas J; Eastell R; Shoback DM; Black DM
J Clin Endocrinol Metab; 2012 Oct; 97(10):3522-9. PubMed ID: 22791766
[TBL] [Abstract][Full Text] [Related]
49. Hetereogeneity in skeletal response to full-length parathyroid hormone in the treatment of osteoporosis.
Sellmeyer DE; Black DM; Palermo L; Greenspan S; Ensrud K; Bilezikian J; Rosen CJ
Osteoporos Int; 2007 Jul; 18(7):973-9. PubMed ID: 17333451
[TBL] [Abstract][Full Text] [Related]
50. Efficacy and safety of monthly oral minodronate in patients with involutional osteoporosis.
Okazaki R; Hagino H; Ito M; Sone T; Nakamura T; Mizunuma H; Fukunaga M; Shiraki M; Nishizawa Y; Ohashi Y; Matsumoto T
Osteoporos Int; 2012 Jun; 23(6):1737-45. PubMed ID: 21932114
[TBL] [Abstract][Full Text] [Related]
51. A phase 2, randomized, placebo-controlled, dose-ranging study of the calcium-sensing receptor antagonist MK-5442 in the treatment of postmenopausal women with osteoporosis.
Halse J; Greenspan S; Cosman F; Ellis G; Santora A; Leung A; Heyden N; Samanta S; Doleckyj S; Rosenberg E; Denker AE
J Clin Endocrinol Metab; 2014 Nov; 99(11):E2207-15. PubMed ID: 25166719
[TBL] [Abstract][Full Text] [Related]
52. Bone mineral density changes in hypercalciuretic osteoporotic men treated with thiazide diuretics.
Legroux-Gerot I; Catanzariti L; Marchandise X; Duquesnoy B; Cortet B
Joint Bone Spine; 2004 Jan; 71(1):51-5. PubMed ID: 14769521
[TBL] [Abstract][Full Text] [Related]
53. ALX 111: ALX1-11, parathyroid hormone (1-84) - NPS Allelix, PREOS, PTH, recombinant human parathyroid hormone, rhPTH (1-84).
Adis International Ltd
Drugs R D; 2003; 4(4):231-5. PubMed ID: 12848587
[TBL] [Abstract][Full Text] [Related]
54. Elevations in serum and urinary calcium with parathyroid hormone (1-84) with and without alendronate for osteoporosis.
Antoniucci DM; Sellmeyer DE; Bilezikian JP; Palermo L; Ensrud KE; Greenspan SL; Black DM
J Clin Endocrinol Metab; 2007 Mar; 92(3):942-7. PubMed ID: 17164314
[TBL] [Abstract][Full Text] [Related]
55. Use of recombinant human parathyroid hormone(1-84) in patients with postmenopausal osteoporosis: a prospective, open-label, single-arm, multicentre, observational cohort study of the effects of treatment on quality of life and pain--the PROPOSE study.
Möricke R; Rettig K; Bethke TD
Clin Drug Investig; 2011; 31(2):87-99. PubMed ID: 21155613
[TBL] [Abstract][Full Text] [Related]
56. [Vitrum osteomag in prevention of osteoporosis in postmenopausal women: results of the comparative open multicenter trial].
Benevolenskaia LI; Toroptsova NV; Nikitinskaia OA; Sharapova EP; Korotkova TA; Rozhinskaia LIa; Marova EI; Dzeranova LK; Molitvoslovova NN; Men'shikova LV; Grudinina OV; Lesniak OM; Evstigneeva LP; Smetnik VP; Shestakova IG; Kuznetsov SIu
Ter Arkh; 2004; 76(11):88-93. PubMed ID: 15658548
[TBL] [Abstract][Full Text] [Related]
57. Osteopontin regulates anabolic effect in human menopausal osteoporosis with intermittent parathyroid hormone treatment.
Chiang TI; Chang IC; Lee HS; Lee H; Huang CH; Cheng YW
Osteoporos Int; 2011 Feb; 22(2):577-85. PubMed ID: 20734029
[TBL] [Abstract][Full Text] [Related]
58. Bone responsiveness to parathyroid hormone in normal and osteoporotic postmenopausal women.
Tsai KS; Ebeling PR; Riggs BL
J Clin Endocrinol Metab; 1989 Nov; 69(5):1024-7. PubMed ID: 2793989
[TBL] [Abstract][Full Text] [Related]
59. The effect of parathyroid hormone (1-84) treatment on serum bone morphogenetic protein 4 and vascular endothelial growth factor in postmenopausal women with established osteoporosis.
Pepe J; Cipriani C; Cantatore FP; Fabbri A; Pola E; Vinicola V; Raimo O; Biamonte F; Pascone R; Ferrara C; Minisola S
J Endocrinol Invest; 2017 Jun; 40(6):663-667. PubMed ID: 28238166
[TBL] [Abstract][Full Text] [Related]
60. Effects of increasing age, dosage, and duration of PTH treatment on BMD increase--a meta-analysis.
Schwarz P; Jorgensen NR; Mosekilde L; Vestergaard P
Calcif Tissue Int; 2012 Mar; 90(3):165-73. PubMed ID: 22237954
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
